Adicet Bio, INC 8-K filings

Adicet Bio, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Adicet Bio announced its first-quarter 2026 financial results, highlighting progress in its autoimmune and cancer cell therapy programs, with key clinical updates anticipated mid-year.

Adicet Bio, Inc. reports an exchange of common stock for a pre-funded warrant with RA Capital Management.

Adicet Bio announced its Q4 and full-year 2025 financial results, highlighting strong clinical progress in autoimmune and solid tumor programs and a solid cash position.

Adicet Bio announced significant progress in its autoimmune and oncology pipelines, including doubled patient enrollment for prula-cel and an extended cash runway into late 2027.

Adicet Bio, Inc. announced a 1-for-16 reverse stock split, effective December 30, 2025, to regain compliance with Nasdaq's minimum bid price requirement.

Adicet Bio, Inc. stockholders approved a reverse stock split at the 2025 Special Meeting, allowing the board to set a ratio between one-for-five and one-for-thirty.

Adicet Bio announced positive preliminary Phase 1 data for ADI-001 in autoimmune diseases and extended its cash runway into 2H/2027 following a $74.8 million capital raise.

Adicet Bio, Inc. received an additional 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, resulting in a transfer to the Nasdaq Capital Market.

Adicet Bio, Inc. announced an underwritten registered direct offering of common stock and pre-funded warrants, expecting to raise approximately $74.8 million in net proceeds.

Adicet Bio announced positive preliminary Phase 1 data for ADI-001 in lupus nephritis and systemic lupus erythematosus, demonstrating high response rates and a favorable safety profile.

Adicet Bio announced its second quarter 2025 financial results, highlighted by progress in its ADI-001 autoimmune program and a strategic pipeline prioritization including a 30% workforce reduction to extend cash runway.

Adicet Bio announced a strategic pipeline prioritization, including a 30% workforce reduction and discontinuation of the ADI-270 program, to extend its cash runway into Q4 2026.

Adicet Bio, Inc. announced the successful outcomes of its 2025 Annual Meeting of Stockholders, where all three proposals, including the election of Class I directors, advisory approval of executive compensation, and ratification of KPMG LLP as auditor, were passed.

Adicet Bio announces its Q1 2025 financial results and provides updates on its clinical programs, including upcoming data readouts for ADI-001 and ADI-270 in the second half of 2025.

Adicet Bio welcomes Michael Grissinger, a seasoned pharmaceutical executive, to its Board of Directors, enhancing the company's strategic capabilities in immunology and business development.

Adicet Bio, Inc. received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, potentially leading to delisting.

Adicet Bio announced its Q4 and full year 2024 financial results, highlighting progress in clinical trials for ADI-001 in autoimmune diseases and ADI-270 in solid tumors, along with a cash position of $176.3 million.

Adicet Bio announces enrollment updates for its ADI-001 and ADI-270 clinical programs at the Guggenheim Securities SMID Cap Biotech Conference.

Adicet Bio has announced the first patient has been dosed in a Phase 1 clinical trial evaluating ADI-270 for metastatic/advanced clear cell renal cell carcinoma.

Adicet Bio has fully repaid its outstanding debt and terminated its loan agreement with Banc of California.

Adicet Bio has announced the start of enrollment for a Phase 1 clinical trial of ADI-270 in metastatic/advanced clear cell renal cell carcinoma and the dosing of the first patient in a Phase 1 trial of ADI-001 for lupus nephritis.

Adicet Bio has amended its loan agreement with Banc of California, modifying collateral requirements and investment limits related to its Shanghai subsidiary.

Adicet Bio announced its third quarter 2024 financial results, highlighted by the expansion of its ADI-001 clinical trial to six autoimmune disease indications and a strong cash position of $202.1 million.

Adicet Bio has received FDA clearance to amend its Investigational New Drug application to include idiopathic inflammatory myopathy and stiff person syndrome in its ongoing Phase 1 trial of ADI-001.

Adicet Bio has opened enrollment for its Phase 1 clinical trial of ADI-001 in autoimmune diseases, including lupus nephritis, with plans to expand to other indications in the fourth quarter of 2024.

Adicet Bio announced positive clinical biomarker data for ADI-001, demonstrating robust tissue trafficking and complete B cell depletion in secondary lymphoid tissue, suggesting potential as a best-in-class therapy for autoimmune diseases.

Adicet Bio is prioritizing the development of ADI-001 for autoimmune diseases, while reporting promising results from a Phase 1 lymphoma study.

Adicet Bio has appointed Lloyd Klickstein, M.D., Ph.D., to its Board of Directors, following the resignation of Michael Kauffman, M.D., Ph.D.

Adicet Bio reported its second quarter 2024 financial results, highlighted by expanded clinical development of ADI-001 and FDA Fast Track Designation for two product candidates.